Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RCAS H3.3WT-P2A-PDGFB is a replication-competent avian sarcoma-leukosis virus (RCAS) vector designed for the co-expression of wild-type histone H3.3 (H3.3WT) and the oncogenic driver platelet-derived growth factor subunit B (PDGFB). Utilizing a self-cleaving P2A peptide, this construct ensures the stoichiometric expression of both proteins from a single transcript. It is primarily used in the RCAS/N-TVA mouse model system to study the pathogenesis of pediatric high-grade gliomas (pHGG). In this research context, it serves as a control or a baseline to compare against mutant histone versions (such as H3.3K27M or H3.3G34R) to determine how specific histone mutations and post-translational modifications influence tumorigenesis and chromatin regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RCAS H3.3WT-P2A-PDGFB.